Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Xilio Therapeutics, Inc.

XLO Nasdaq SEC CIK 1840233
Follow Xilio Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $18.7M +131.2% vs same quarter last year
Net income −$6.4M +59.8% vs same quarter last year
EPS, diluted −$0.33 +85.7% vs same quarter last year
Operating cash flow −$18.8M −29.6% vs same quarter last year
Revenue by quarter
$2.3M
$1.7M
$2.9M
$8.1M
$19.1M
$13.7M
$12.6M
$18.7M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$35M
FY24−$58.2M
FY23−$76.4M
FY22−$88.2M
FY21−$75.8M
FY20−$55.2M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$5.5M
FY24−$18.4M
FY23−$69.1M
FY22−$77.6M
FY21−$81.9M
FY20−$38.3M
FY19-

News

No stories filed under Xilio Therapeutics yet - coverage appears here as the news feed clusters it.